Education and Training
- Fellow, Infectious Diseases, Duke University School of Medicine, 2008 - 2010
- Resident, Internal Medicine, Duke University School of Medicine, 2005 - 2008
- M.D., Wake Forest University, 2005
Turner, Nicholas A., Batu K. Sharma-Kuinkel, Stacey A. Maskarinec, Emily M. Eichenberger, Pratik P. Shah, Manuela Carugati, Thomas L. Holland, and Vance G. Fowler. “Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research..” Nature Reviews. Microbiology 17, no. 4 (April 2019): 203–18. https://doi.org/10.1038/s41579-018-0147-4.
Holland, Thomas L., Henry F. Chambers, Helen W. Boucher, G Ralph Corey, Rebecca Coleman, Bibiana Castaneda-Ruiz, and Vance G. Fowler. “Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults..” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 68, no. 5 (February 2019): 865–72. https://doi.org/10.1093/cid/ciy774.
Huang, David B., Sophie Magnet, Stefania De Angelis, Thomas L. Holland, Thomas M. File, Matthew Dryden, G Ralph Corey, Antoni Torres, and Mark H. Wilcox. “Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe..” Diagnostic Microbiology and Infectious Disease 93, no. 2 (February 2019): 154–58. https://doi.org/10.1016/j.diagmicrobio.2018.09.002.
Radovanovic, Dejan, Giovanni Sotgiu, Mateja Jankovic, Padukudru Anand Mahesh, Pedro Jorge Marcos, Mohamed I. Abdalla, Marta Francesca Di Pasquale, et al. “An international perspective on hospitalized patients with viral community-acquired pneumonia..” European Journal of Internal Medicine 60 (February 2019): 54–70. https://doi.org/10.1016/j.ejim.2018.10.020.
Evans, Scott R., Dean Follmann, Ying Liu, Thomas Holland, Sarah B. Doernberg, Nadine Rouphael, Toshimitsu Hamasaki, et al. “Sequential Multiple Assignment Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS)..” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, October 23, 2018. https://doi.org/10.1093/cid/ciy912.
Doernberg, Sarah B., Thuy Tien Tram Tran, Steven Y. C. Tong, Mical Paul, Dafna Yahav, Joshua S. Davis, Leonard Leibovici, et al. “Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection..” Clin Infect Dis, October 12, 2018. https://doi.org/10.1093/cid/ciy766.
Holland, Thomas L., Issam Raad, Helen W. Boucher, Deverick J. Anderson, Sara E. Cosgrove, P Suzanne Aycock, John W. Baddley, et al. “Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial..” Jama 320, no. 12 (September 2018): 1249–58. https://doi.org/10.1001/jama.2018.13155.
Restrepo, Marcos I., Bettina L. Babu, Luis F. Reyes, James D. Chalmers, Nilam J. Soni, Oriol Sibila, Paola Faverio, et al. “Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients..” The European Respiratory Journal 52, no. 2 (August 9, 2018). https://doi.org/10.1183/13993003.01190-2017.
Huang, David B., G Ralph Corey, Thomas L. Holland, Thomas Lodise, William O’Riordan, Mark H. Wilcox, Thomas M. File, et al. “Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections..” International Journal of Antimicrobial Agents 52, no. 2 (August 2018): 233–40. https://doi.org/10.1016/j.ijantimicag.2018.05.012.
Holland, Thomas L., William O’Riordan, Alison McManus, Elliot Shin, Ali Borghei, Thomas M. File, Mark H. Wilcox, et al. “A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)..” Antimicrob Agents Chemother 62, no. 5 (May 2018). https://doi.org/10.1128/AAC.02580-17.